- Home
- NGL vs CAPR Comparison
NGL vs CAPR Comparison
Compare NGL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGL
- CAPR
- Stock Information
- Founded
- NGL 1940
- CAPR 2005
- Country
- NGL United States
- CAPR United States
- Employees
- NGL N/A
- CAPR N/A
- Industry
- NGL Natural Gas Distribution
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NGL Utilities
- CAPR Health Care
- Exchange
- NGL Nasdaq
- CAPR Nasdaq
- Market Cap
- NGL 645.5M
- CAPR 578.4M
- IPO Year
- NGL 2011
- CAPR N/A
- Fundamental
- Price
- NGL $4.79
- CAPR $15.00
- Analyst Decision
- NGL
- CAPR Strong Buy
- Analyst Count
- NGL 0
- CAPR 7
- Target Price
- NGL N/A
- CAPR $39.29
- AVG Volume (30 Days)
- NGL 620.9K
- CAPR 902.1K
- Earning Date
- NGL 02-10-2025
- CAPR 03-03-2025
- Dividend Yield
- NGL N/A
- CAPR N/A
- EPS Growth
- NGL N/A
- CAPR N/A
- EPS
- NGL N/A
- CAPR N/A
- Revenue
- NGL $5,918,601,000.00
- CAPR $23,228,045.00
- Revenue This Year
- NGL N/A
- CAPR N/A
- Revenue Next Year
- NGL N/A
- CAPR $74.85
- P/E Ratio
- NGL N/A
- CAPR N/A
- Revenue Growth
- NGL N/A
- CAPR 65.33
- 52 Week Low
- NGL $3.84
- CAPR $3.52
- 52 Week High
- NGL $6.20
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- NGL 43.51
- CAPR 52.56
- Support Level
- NGL $4.21
- CAPR $14.28
- Resistance Level
- NGL $5.08
- CAPR $16.47
- Average True Range (ATR)
- NGL 0.27
- CAPR 1.00
- MACD
- NGL -0.06
- CAPR 0.07
- Stochastic Oscillator
- NGL 38.16
- CAPR 55.05
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, and for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.